LRSSL: predict and interpret drug‐disease associations based on data integration using sparse subspace learning

Motivation : Exploring the potential curative effects of drugs is crucial for effective drug development. Previous studies have indicated that integration of multiple types of information could be conducive to discovering novel indications of drugs. However, how to efficiently identify the mechanism behind drug‐disease associations while integrating data from different sources remains a challenging problem. Results : In this research, we present a novel method for indication prediction of both new drugs and approved drugs. This method is based on Laplacian regularized sparse subspace learning (LRSSL), which integrates drug chemical information, drug target domain information and target annotation information. Experimental results show that the proposed method outperforms several recent approaches for predicting drug‐disease associations. Some drug therapeutic effects predicted by the method could be validated by database records or literatures. Moreover, with L1‐norm constraint, important drug features have been extracted from multiple drug feature profiles. Case studies suggest that the extracted drug features could be beneficial to interpretation of the predicted results. Availability and Implementation: https://github.com/LiangXujun/LRSSL Contact: proteomics@csu.edu.cn Supplementary information: Supplementary data are available at Bioinformatics online.

[1]  Baris E. Suzek,et al.  The Universal Protein Resource (UniProt) in 2010 , 2009, Nucleic Acids Res..

[2]  Ping Zhang,et al.  Exploring the associations between drug side-effects and therapeutic indications , 2014, J. Biomed. Informatics.

[3]  Cam Patterson,et al.  The Role of Calcineurin/NFAT in SFRP2 Induced Angiogenesis—A Rationale for Breast Cancer Treatment with the Calcineurin Inhibitor Tacrolimus , 2011, PloS one.

[4]  Larry Rubinstein,et al.  A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas , 2012, Clinical Cancer Research.

[5]  María Martín,et al.  The Universal Protein Resource (UniProt) in 2010 , 2010 .

[6]  Cheng Yuan-sen,et al.  128 cases of myasthenia gravis treated with huperzine A , 1986 .

[7]  Peer Bork,et al.  The SIDER database of drugs and side effects , 2015, Nucleic Acids Res..

[8]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[9]  Yang Song,et al.  Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery , 2011, Nucleic Acids Res..

[10]  Julio Gálvez,et al.  The intestinal anti-inflammatory effect of minocycline in experimental colitis involves both its immunomodulatory and antimicrobial properties. , 2011, Pharmacological research.

[11]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[12]  Chris H. Q. Ding,et al.  Convex and Semi-Nonnegative Matrix Factorizations , 2010, IEEE Transactions on Pattern Analysis and Machine Intelligence.

[13]  Qiuqi Ruan,et al.  Semi-supervised sparse feature selection based on multi-view Laplacian regularization , 2015, Image Vis. Comput..

[14]  G. Yochum,et al.  A Role for MYC in Lithium-Stimulated Repair of the Colonic Epithelium After DSS-Induced Damage in Mice , 2016, Digestive Diseases and Sciences.

[15]  Thomas C. Wiegers,et al.  The Comparative Toxicogenomics Database's 10th year anniversary: update 2015 , 2014, Nucleic Acids Res..

[16]  Mona Soliman,et al.  Preservation of myocardial contractile function by aminoguanidine, a nitric oxide synthase inhibitors, in a rat model of hemorrhagic shock , 2013, Pakistan journal of medical sciences.

[17]  Alexander A. Morgan,et al.  Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.

[18]  R. Sharan,et al.  PREDICT: a method for inferring novel drug indications with application to personalized medicine , 2011, Molecular systems biology.

[19]  A. Chiang,et al.  Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses , 2009, Clinical pharmacology and therapeutics.

[20]  Yongcui Wang,et al.  Drug Repositioning by Kernel-Based Integration of Molecular Structure, Molecular Activity, and Phenotype Data , 2013, PloS one.

[21]  Xiang Zhang,et al.  Drug repositioning by integrating target information through a heterogeneous network model , 2014, Bioinform..

[22]  Csaba Szabó,et al.  Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock , 1995, British journal of pharmacology.

[23]  Yanli Wang,et al.  PubChem: a public information system for analyzing bioactivities of small molecules , 2009, Nucleic Acids Res..

[24]  Oakland J. Peters,et al.  Predicting new indications for approved drugs using a proteochemometric method. , 2012, Journal of medicinal chemistry.

[25]  David Heckerman,et al.  Empirical Analysis of Predictive Algorithms for Collaborative Filtering , 1998, UAI.

[26]  Yoshihiro Yamanishi,et al.  Systematic Drug Repositioning for a Wide Range of Diseases with Integrative Analyses of Phenotypic and Molecular Data , 2015, J. Chem. Inf. Model..

[27]  Dong Wang,et al.  Inferring the human microRNA functional similarity and functional network based on microRNA-associated diseases , 2010, Bioinform..

[28]  Huaiyu Mi,et al.  The InterPro protein families database: the classification resource after 15 years , 2014, Nucleic Acids Res..

[29]  Mona M. Soliman,et al.  Effects of aminoguanidine, a potent nitric oxide synthase inhibitor, on myocardial and organ structure in a rat model of hemorrhagic shock , 2014, Journal of emergencies, trauma, and shock.

[30]  P. Sanseau,et al.  Computational Drug Repositioning: From Data to Therapeutics , 2013, Clinical pharmacology and therapeutics.

[31]  Pankaj Agarwal,et al.  Systematic Drug Repositioning Based on Clinical Side-Effects , 2011, PloS one.

[32]  Hyunsoo Kim,et al.  Sparse Non-negative Matrix Factorizations via Alternating Non-negativity-constrained Least Squares , 2006 .

[33]  Martyna Elas,et al.  Lifespan of etoposide-treated human neutrophils is affected by antioxidant ability of quercetin. , 2007, Toxicology in vitro : an international journal published in association with BIBRA.